# A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

> **NCT04442503** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 200 (actual)

## Conditions studied

- Depression, Postpartum

## Interventions

- **DRUG:** SAGE-217
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04442503
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-08
- **Primary completion:** 2022-03-15
- **Final completion:** 2022-04-12
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04442503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04442503, "A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04442503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*